Atrial fibrillation/flutter (AF) is a major public health problem and is associated with stroke, heart failure, dementia, and death. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Metformin is an orally effective anti-hyperglycemic drug that despite being introduced over 60 years ago is still utilized by an estimated 120 to 150 million people worldwide for the treatment of type 2 diabetes (T2D). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD) are chronic, progressive disorders affecting the elderly, which fosters global healthcare concern with the growing aging population. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Obesity has been linked to a range of pathologies, including dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Obstructive sleep apnea is one of the most common sleep disorders. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Sensory loss in olfaction, vision, and hearing is a risk factor for dementia, but the reasons for this are unclear. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Several studies have been done to investigate the role of hearing loss (HL) in cognitive decline. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Two-hundred and seventy-three subjects were included, 189 normal hearing and 84 subjective hearing loss subjects. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In the course of several neurodegenerative conditions, the presence of a sensory alteration, even before the appearance of cognitive disorders or complaints concerning autonomy, can potentially lead to earlier diagnosis and more efficient management of these complex patients. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
43/100
In this perspective article, the author explores the connections between hearing loss, central auditory processing, and cognitive decline, offering insights into the complex dynamics at play. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Atrial fibrillation (AF) is the most common cardiac arrhythmia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) prevalence has increased in the last century which can be attributed to increased lifespan, but environment is also important. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Over 35% of the adult US population is obese. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Due to increasing lifespan and aging populations globally there has been a steep rise in late-life dementia, which is now the second most common cause of death in high-income countries. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Diabetes mellitus (DM) and Alzheimer's disease (AD) are two major health concerns that have seen a rising prevalence worldwide. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Social connectedness is important for maintaining cognitive function and cognitive health in older age. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Air pollution is a critical global issue with extensive implications beyond respiratory health, significantly affecting neurological and psychiatric disorders. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This paper delves into the increasingly recognized yet complex relationship between air pollution and Neurological Diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease and related dementias are a leading cause of morbidity in our aging populations. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
43/100
Environmental pollution exposures, including air, soil, water, light, and noise pollution, are critical issues that may implicate adverse mental health outcomes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our MR analysis identified a notable association between genetically predicted PM2.5 (PM with a diameter of 2.5 μm or less) exposure and an elevated risk of AD (odds ratio, 2.160; 95% confidence interval, 1.481 to 3.149; p < 0.001). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is one of the most significant global challenges in medical and social care in the 21st century. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
43/100
The gastrointestinal (GI) tract, home to the largest microbial population in the human body, plays a crucial role in overall health through various mechanisms. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Worldwide, around 50 million people live with dementia, and this number is projected to triple by 2050. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cerebral small vessel disease (CSVD) is a group of pathologies that affect the cerebral blood vessels. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- The Association of Apathy With Incident Dementia: A Multiple Mediation Analysis of Cardiovascular Risk Factors
- Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers
- Neurodegenerative disorders associated with diabetes mellitus
- MIND diet and the risk of dementia: a population-based study
- Abdominal obesity and the risk of young-onset dementia in women: a nationwide cohort study
- Cognitive decline and dementia in diabetes--systematic overview of prospective observational studies
- Effects of air pollution on dementia over Europe for present and future climate change scenarios
- Hearing Loss and Cognitive Impairment: Epidemiology, Common Pathophysiological Findings, and Treatment Considerations
- Diabetes in midlife and cognitive change over 20 years: a cohort study
- Greater socioenvironmental risk factors and higher chronic pain stage are associated with thinner bilateral temporal lobes
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →